Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

Fredrick L. Dunn, Linda S. Higgins, Jill Fredrickson, Alex M. Depaoli

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Objective: INT131 besylate is a potent non-thiazolidinedione selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve insulin sensitivity and glucose metabolism while minimizing the side effects of full agonist thiazolidinediones. This study was conducted to determine short-term efficacy and safety of INT131 besylate in patients with Type 2 diabetes mellitus (T2DM). Research Design and Methods: This was a 4-week randomized, double-blind, placebo-controlled multi-center study with 1 or 10mg INT131 besylate or placebo daily in subjects with T2DM not receiving pharmacotherapy for their hyperglycemia. The primary efficacy analysis was the comparison of treatment groups with respect to least square mean change from baseline to Week 4 of fasting plasma glucose (FPG). Results: Baseline mean (±S.D.) FPG for the study population was 171±42 mg/dl. Change in FPG (±S.E., mg/dl) from baseline after 4 weeks was 8±8 (P=NS) with placebo, -22±8 with 1mg INT131 besylate (P=.0056) and -46±7 with 10mg INT131 besylate (P<.0001). Modeling of available data from the literature of the effect of rosiglitazone under similar study conditions suggested that 1 mg of INT131 besylate had a similar reduction in FPG as expected with 8 mg of rosiglitazone. INT131 besylate was well tolerated, and the 1 mg dose demonstrated no evidence of fluid retention or weight gain. Conclusions: INT131 besylate demonstrated a dose dependent reduction in FPG. The FPG reduction with 1mg INT131 besylate was comparable to the modeled 8 mg dose of rosiglitazone, and did not cause fluid retention or weight gain. These results are consistent with the INT131 SPPARM design.

Original languageEnglish (US)
Pages (from-to)151-158
Number of pages8
JournalJournal of Diabetes and its Complications
Volume25
Issue number3
DOIs
StatePublished - May 2011

Fingerprint

Benzenesulfonates
Peroxisome Proliferator-Activated Receptors
Type 2 Diabetes Mellitus
rosiglitazone
Glucose
Fasting
Placebos
Weight Gain
INT 131
2,4-thiazolidinedione
Thiazolidinediones
Least-Squares Analysis
Hyperglycemia

Keywords

  • Insulin sensitization
  • INT131
  • Non-thiazolidinedione
  • PPARγ
  • SPPARM

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes. / Dunn, Fredrick L.; Higgins, Linda S.; Fredrickson, Jill; Depaoli, Alex M.

In: Journal of Diabetes and its Complications, Vol. 25, No. 3, 05.2011, p. 151-158.

Research output: Contribution to journalArticle

@article{a6191b2fa01b47f689325936218a2f40,
title = "Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes",
abstract = "Objective: INT131 besylate is a potent non-thiazolidinedione selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve insulin sensitivity and glucose metabolism while minimizing the side effects of full agonist thiazolidinediones. This study was conducted to determine short-term efficacy and safety of INT131 besylate in patients with Type 2 diabetes mellitus (T2DM). Research Design and Methods: This was a 4-week randomized, double-blind, placebo-controlled multi-center study with 1 or 10mg INT131 besylate or placebo daily in subjects with T2DM not receiving pharmacotherapy for their hyperglycemia. The primary efficacy analysis was the comparison of treatment groups with respect to least square mean change from baseline to Week 4 of fasting plasma glucose (FPG). Results: Baseline mean (±S.D.) FPG for the study population was 171±42 mg/dl. Change in FPG (±S.E., mg/dl) from baseline after 4 weeks was 8±8 (P=NS) with placebo, -22±8 with 1mg INT131 besylate (P=.0056) and -46±7 with 10mg INT131 besylate (P<.0001). Modeling of available data from the literature of the effect of rosiglitazone under similar study conditions suggested that 1 mg of INT131 besylate had a similar reduction in FPG as expected with 8 mg of rosiglitazone. INT131 besylate was well tolerated, and the 1 mg dose demonstrated no evidence of fluid retention or weight gain. Conclusions: INT131 besylate demonstrated a dose dependent reduction in FPG. The FPG reduction with 1mg INT131 besylate was comparable to the modeled 8 mg dose of rosiglitazone, and did not cause fluid retention or weight gain. These results are consistent with the INT131 SPPARM design.",
keywords = "Insulin sensitization, INT131, Non-thiazolidinedione, PPARγ, SPPARM",
author = "Dunn, {Fredrick L.} and Higgins, {Linda S.} and Jill Fredrickson and Depaoli, {Alex M.}",
year = "2011",
month = "5",
doi = "10.1016/j.jdiacomp.2010.06.006",
language = "English (US)",
volume = "25",
pages = "151--158",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes

AU - Dunn, Fredrick L.

AU - Higgins, Linda S.

AU - Fredrickson, Jill

AU - Depaoli, Alex M.

PY - 2011/5

Y1 - 2011/5

N2 - Objective: INT131 besylate is a potent non-thiazolidinedione selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve insulin sensitivity and glucose metabolism while minimizing the side effects of full agonist thiazolidinediones. This study was conducted to determine short-term efficacy and safety of INT131 besylate in patients with Type 2 diabetes mellitus (T2DM). Research Design and Methods: This was a 4-week randomized, double-blind, placebo-controlled multi-center study with 1 or 10mg INT131 besylate or placebo daily in subjects with T2DM not receiving pharmacotherapy for their hyperglycemia. The primary efficacy analysis was the comparison of treatment groups with respect to least square mean change from baseline to Week 4 of fasting plasma glucose (FPG). Results: Baseline mean (±S.D.) FPG for the study population was 171±42 mg/dl. Change in FPG (±S.E., mg/dl) from baseline after 4 weeks was 8±8 (P=NS) with placebo, -22±8 with 1mg INT131 besylate (P=.0056) and -46±7 with 10mg INT131 besylate (P<.0001). Modeling of available data from the literature of the effect of rosiglitazone under similar study conditions suggested that 1 mg of INT131 besylate had a similar reduction in FPG as expected with 8 mg of rosiglitazone. INT131 besylate was well tolerated, and the 1 mg dose demonstrated no evidence of fluid retention or weight gain. Conclusions: INT131 besylate demonstrated a dose dependent reduction in FPG. The FPG reduction with 1mg INT131 besylate was comparable to the modeled 8 mg dose of rosiglitazone, and did not cause fluid retention or weight gain. These results are consistent with the INT131 SPPARM design.

AB - Objective: INT131 besylate is a potent non-thiazolidinedione selective peroxisome proliferator-activated receptor γ (PPARγ) modulator (SPPARM) designed to improve insulin sensitivity and glucose metabolism while minimizing the side effects of full agonist thiazolidinediones. This study was conducted to determine short-term efficacy and safety of INT131 besylate in patients with Type 2 diabetes mellitus (T2DM). Research Design and Methods: This was a 4-week randomized, double-blind, placebo-controlled multi-center study with 1 or 10mg INT131 besylate or placebo daily in subjects with T2DM not receiving pharmacotherapy for their hyperglycemia. The primary efficacy analysis was the comparison of treatment groups with respect to least square mean change from baseline to Week 4 of fasting plasma glucose (FPG). Results: Baseline mean (±S.D.) FPG for the study population was 171±42 mg/dl. Change in FPG (±S.E., mg/dl) from baseline after 4 weeks was 8±8 (P=NS) with placebo, -22±8 with 1mg INT131 besylate (P=.0056) and -46±7 with 10mg INT131 besylate (P<.0001). Modeling of available data from the literature of the effect of rosiglitazone under similar study conditions suggested that 1 mg of INT131 besylate had a similar reduction in FPG as expected with 8 mg of rosiglitazone. INT131 besylate was well tolerated, and the 1 mg dose demonstrated no evidence of fluid retention or weight gain. Conclusions: INT131 besylate demonstrated a dose dependent reduction in FPG. The FPG reduction with 1mg INT131 besylate was comparable to the modeled 8 mg dose of rosiglitazone, and did not cause fluid retention or weight gain. These results are consistent with the INT131 SPPARM design.

KW - Insulin sensitization

KW - INT131

KW - Non-thiazolidinedione

KW - PPARγ

KW - SPPARM

UR - http://www.scopus.com/inward/record.url?scp=79955064893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955064893&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2010.06.006

DO - 10.1016/j.jdiacomp.2010.06.006

M3 - Article

C2 - 20739195

AN - SCOPUS:79955064893

VL - 25

SP - 151

EP - 158

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 3

ER -